Loading organizations...

§ Public · Munich, Bayern, Germany
Clinical-stage biopharmaceutical company developing psychedelic & non-psychedelic therapeutics for depression, anxiety, addiction.
Based in Berlin, Germany, atai Life Sciences is a clinical-stage biopharmaceutical company operating a decentralized platform to develop psychedelic and non-psychedelic therapeutics for severe mental health disorders. The publicly traded firm utilizes a hub-and-spoke model to incubate subsidiary companies, raising $225 million during its June 2021 NASDAQ IPO at a valuation exceeding $2 billion. Following a clinical trial setback in 2023 that resulted in a 30% staff reduction, the enterprise reported holding approximately $154 million in cash reserves by early 2024. Backed by prominent early investor Peter Thiel, the organization maintains strategic investments across the psychiatric medicine sector, including a 22.4% equity stake in COMPASS Pathways and a $50 million investment in Beckley Psytech. The biopharmaceutical business atai Life Sciences was founded in 2018 by Christian Angermayer, Florian Brand, Lars Christian Wilde, and Srinivas Rao.
atai Life Sciences has raised $505.0M across 5 funding rounds.
Key people at atai Life Sciences.
atai Life Sciences was founded in 2018 by Srinivas Rao (Co-Founder & Chief Scientific Officer) and Lars Christian Wilde (Co-Founder) and Florian Brand (CEO and Co-Founder).
atai Life Sciences has raised $505.0M in total across 5 funding rounds.
atai Life Sciences has raised $505.0M across 5 funding rounds. Most recently, it raised $175.0M Debt in August 2022.
# atai Life Sciences: Correcting the Classification
atai Life Sciences is not a technology company—it is a clinical-stage biopharmaceutical company focused on developing innovative mental health treatments, particularly psychedelic-based therapies[1][4].
atai Life Sciences operates as a biopharmaceutical platform company with a mission to develop highly effective mental health treatments that address significant unmet medical needs[1][4]. Rather than building software or technology products, the company acquires, incubates, and advances drug candidates through clinical trials, with a particular focus on psychedelic-based neuroplastogens and rapid-acting psychiatric interventions[1][4].
The company serves patients suffering from mental health disorders, addressing a critical global need: over one billion people live with mental health conditions worldwide, yet most lack access to effective care[3]. atai's approach centers on compounds with prior evidence in human use to minimize development risk, pooling resources to accelerate responsible drug development[2].
atai operates at the intersection of psychiatric innovation and the emerging psychedelic medicine field. The company is positioned to capitalize on growing clinical evidence supporting psychedelic-assisted therapies for treatment-resistant depression and social anxiety disorder[4]. By developing interventional psychiatry solutions designed to integrate into existing healthcare systems, atai addresses both the scientific frontier and the practical challenge of scalable mental health treatment delivery[4].
atai's success hinges on advancing its clinical pipeline through regulatory approval while demonstrating that psychedelic-based treatments can achieve sustained behavioral change in mental health patients[1][4]. The 2025 combination with Beckley Psytech positions the company as a leader in rapid-acting, accessible psychedelic treatments, with potential first-in-class and best-in-class assets in development[4]. As mental health treatment paradigms shift toward novel neuroplastogenic compounds, atai's focused approach to evidence-based drug development could reshape how psychiatric conditions are treated globally.
atai Life Sciences was founded in 2018 by Srinivas Rao (Co-Founder & Chief Scientific Officer) and Lars Christian Wilde (Co-Founder) and Florian Brand (CEO and Co-Founder).
atai Life Sciences has raised $505.0M in total across 5 funding rounds.
atai Life Sciences's investors include Christian Angermayer, Apeiron Investment Group, Thiel Capital, Catalio Capital Management, Falcon Edge Capital, Fearless Ventures, Highline Capital Management, Pura Vida Investments, Michael Auerbach, Woodline Partners, Jacob Vogelstein, Endeavor8.
Key people at atai Life Sciences.